Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269267 · ClinicalTrials.gov registry record · Phase 2
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT02269267: Completed Phase 2 study, sponsored by Medical College of Wisconsin.
NCT02269267 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 173 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02269267, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
Primary Outcome
The number of patients who develop molecular recurrence after discontinuing TKIs. This will be reported as the number of new occurrences from the end of the prior time frame.
Interventions
- DRUG Imatinib (Stopping their TKI)
- DRUG Dasatinib (Stopping their TKI)
- DRUG Nilotinib (Stopping their TKI)
- DRUG Bosutinib (Stopping their TKI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 2 |
What the finished NCT02269267 record still lists
NCT02269267 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which Imatinib (Stopping their TKI) is the first listed.
NCT02269267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02269267 about?
NCT02269267 is a clinical study titled "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)". This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
What is the current status of trial NCT02269267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2014-12-18. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT02269267?
The interventions under investigation include: Imatinib (Stopping their TKI) (DRUG), Dasatinib (Stopping their TKI) (DRUG), Nilotinib (Stopping their TKI) (DRUG), Bosutinib (Stopping their TKI) (DRUG).
Who is sponsoring clinical trial NCT02269267?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02269267's enrollment target sits among peer trials
173 397th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI